for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Flexion Therapeutics Inc

FLXN.OQ

Latest Trade

14.97USD

Change

0.25(+1.70%)

Volume

561,396

Today's Range

14.49

 - 

15.10

52 Week Range

8.78

 - 

19.82

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
14.72
Open
14.71
Volume
561,396
3M AVG Volume
12.60
Today's High
15.10
Today's Low
14.49
52 Week High
19.82
52 Week Low
8.78
Shares Out (MIL)
38.11
Market Cap (MIL)
570.46
Forward P/E
-3.81
Dividend (Yield %)
--

Latest Developments

More

Flexion Therapeutics Posts Qtrly Loss Per Share Of $0.96

Flexion Therapeutics Announces Publication Of Independent Data Review Of Zilretta In The Journal Drugs

Flexion Therapeutics Announces Preliminary, Unaudited Q4 2018 Results

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Flexion Therapeutics Inc

Flexion Therapeutics, Inc. is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company's lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid. The Company is developing Zilretta as a treatment for patients with moderate to severe OA knee pain. The Company has specifically designed Zilretta to combine a steroid, triamcinolone acetonide (TCA) with poly lactic-co-glycolic acid (PLGA), for providing sustained therapeutic concentrations in the joint and persistent analgesic effect. The Company's other product candidates include FX007 for post-operative pain and FX005 for the treatment of end-stage OA patients. The Company is engaged in conducting a Phase IIb clinical trial of Zilretta.

Industry

Biotechnology & Drugs

Contact Info

10 Mall Rd Ste 301

+1.781.3057777

http://flexiontherapeutics.com/

Executive Leadership

Patrick J. Mahaffy

Independent Chairman of the Board

Michael D. Clayman

President, Chief Executive Officer, Director

David A. Arkowitz

Chief Financial Officer

Neil Bodick

Chief Scientific Officer

Mark Levine

General Counsel and Corporate Secretary

Key Stats

1.78 mean rating - 9 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.1K
EPS (USD)

2016

-2.840

2017

-4.160

2018

-4.490

2019(E)

-3.913
Price To Earnings (TTM)
--
Price To Sales (TTM)
12.95
Price To Book (MRQ)
13.76
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
380.99
LT Debt To Equity (MRQ)
380.99
Return on Investment (TTM)
-60.02
Return on Equity (TTM)
-54.53

Latest News

BRIEF-Flexion Therapeutics Q1 Loss Per Share $1.10

* FLEXION THERAPEUTICS REPORTS FIRST-QUARTER 2018 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS

BRIEF-Flexion Therapeutics Names David Arkowitz As Chief Financial Officer

* FLEXION THERAPEUTICS NAMES DAVID ARKOWITZ AS CHIEF FINANCIAL OFFICER

BRIEF-Flexion Therapeutics Reports Q4 Sales $355,000

* FLEXION THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Flexion Therapeutics Announces Initial Data From Clinical Trial Evaluating Repeat Administration Of Zilretta

* FLEXION THERAPEUTICS ANNOUNCES INITIAL DATA FROM CLINICAL TRIAL EVALUATING REPEAT ADMINISTRATION OF ZILRETTA™ (TRIAMCINOLONE ACETONIDE EXTENDED-RELEASE INJECTABLE SUSPENSION)

BRIEF-Flexion Therapeutics Enrolls First Patient In Phase 2 Pharmacokinetics And Safety Study Of Zilretta

* FLEXION THERAPEUTICS ENROLLS FIRST PATIENT IN PHASE 2 PHARMACOKINETICS AND SAFETY STUDY OF ZILRETTA™ (TRIAMCINOLONE ACETONIDE EXTENDED-RELEASE INJECTABLE SUSPENSION) IN BILATERAL OSTEOARTHRITIS OF THE KNEE Source text for Eikon: Further company coverage:

BRIEF-Flexion therapeutics reports third-quarter results

* Flexion Therapeutics reports third-quarter 2017 financial results and recent business highlights

BRIEF-Flexion Therapeutics announces pricing of public offering of common stock

* Flexion Therapeutics announces pricing of public offering of common stock

BRIEF-Flexion Therapeutics- Proposed public offering of 4 mln common shares

* Flexion Therapeutics announces proposed public offering of common stock

Flexion's knee pain drug gets FDA nod, shares hit life high

Flexion Therapeutics Inc said its injectable drug to treat osteoarthritis-related knee pain was approved by the U.S. Food and Drug Administration, sending the drug developer's shares soaring to a record high in regular trading on Friday.

BRIEF-Flexion Therapeutics announces FDA approval of Zilretta for osteoarthritis knee pain

* Flexion Therapeutics announces FDA approval of Zilretta (triamcinolone acetonide extended-release injectable suspension) for osteoarthritis (OA) knee pain

Flexion's knee pain drug gets FDA nod

Flexion Therapeutics Inc said on Friday the U.S. Food and Drug Administration approved its drug, Zilretta, to treat moderate-to-severe osteoarthritis-related knee pain.

BRIEF-Flexion Therapeutics says co sent a notice of termination to Astrazeneca AB regarding an out-license agreement between parties​

* Flexion Therapeutics Inc - on September 8, co sent a notice of termination to Astrazeneca AB regarding an out-license agreement between parties

BRIEF-Flexion Therapeutics qtrly loss per share $0.91

* Flexion therapeutics reports second quarter 2017 financial results and recent business highlights

BRIEF-Flexion Therapeutics files for stock shelf of upto $300 mln

* Flexion Therapeutics Inc files for stock shelf of upto $300 million - SEC filing Source text: (http://bit.ly/2tyVKyT) Further company coverage:

BRIEF-Flexion Therapeutics qtrly loss per share $0.75

* Flexion Therapeutics reports first quarter 2017 financial results and recent business highlights

BRIEF-Flexion Therapeutics announces pricing of $175 mln of senior notes

* Flexion Therapeutics announces pricing of $175 million 3.375% convertible senior notes due 2024

BRIEF-Flexion expects to have $187.5 mln in cash, cash equivalents, and marketable securities as of March 31

* Flexion Therapeutics Inc estimates that, as of March 31, 2017, it had $187.5 million in cash, cash equivalents, and marketable securities Source text - http://bit.ly/2q2e2n1 Further company coverage:

BRIEF-Flexion Therapeutics announces proposed convertible senior notes offering

* Flexion Therapeutics announces proposed convertible senior notes offering

BRIEF-Flexion reports year-end 2016 financial results

* Frederick Driscoll, chief financial officer, intends to retire effective March 31, 2017

BRIEF-Flexion Therapeutics announces NDA for Zilretta accepted by U.S. FDA

* Flexion Therapeutics announces new drug application for Zilretta (fx006) accepted by U.S. Food and Drug Administration

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up